anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hospital-acquired resistant infections (HARI) are infections, which develop 48 h or more after admission to a healthcare facility. HARI pose a considerably acute challenge, due to limited treatment options. These infections are associated bacterial biofilms, which act as a physical barrier to diverse external stresses, such as desiccation, antimicrobials and biocides. We assessed the influence of multiple factors on biofilm production by HARI -associated bacteria.
METHODS: Bacteria were isolated from samples of patients with respiratory HARI who were hospitalized during 2020-2022 in north Israel. Following antibiotic susceptibility testing by disc diffusion or broth microdilution, biofilm formation capacities of resistant bacteria (methicillin-resistant staphylococcus aureus, extended spectrum beta-lactamase-producing Escherichia coli and Klebsiela pneumonia, and multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii) was assessed using the crystalline violet staining method. Data regarding season, time to infection, bacterial species, patient age and gender, year, and medical department were collected from the patient medical records.
RESULTS: Among the 226 study isolates, K. pneumonia was the most prevalent (35.4%) bacteria, followed by P. aeruginosa (23.5%), and methicillin-resistant staphylococcus aureus (MRSA) (21.7%). A significantly higher rate of HARI was documented in 2022 compared to 2020-2021. The majority of isolates (63.3%) were strong biofilm producers, with K. pneumonia (50.3%) being most dominant, followed by P. aeruginosa (29.4%). Biofilm production strength was significantly affected by seasonality and hospitalization length, with strong biofilm production in autumn and in cases where hospitalization length exceeded 30 days.
CONCLUSION: Biofilm production by HARI bacteria is influenced by bacterial species, season and hospitalization length.
PROBLEM TO BE SOLVED: To obtain a dentifrice agent which has sterilization, plaque removing effects, improving the absorption of medicable ingredients having circulation accelerating effect using a promoting effect of percutaneous absorption through gum, effective in a short time by containing alcoholic extract of Impatience balsamina L. SOLUTION: The alcoholic extract of Impatience balsamina L is obtained by immersing 2-5 pts.wt. of the whole of Impatience balsamina L, petal, seed which are collected, sun dried as needed, cut out, in 10 pts.wt. of aqueous solution of ethyl alcohol of 10 of more alcohol content(e.g. white liquor) for 2 weeks- half a year, then the residue is separated in a process such as dry-mesh process, etc. The dentifrice agent is obtained by containing 5-10wt.%. of this alcoholic extract in conventional dentifrice agent component such as tooth paste, wet dental powder, liquid dentifrice agent, etc. The alcoholic solution of fruits such as Psidium guajava, grape-fruit, tangerine, lemon, etc., extracted in the prescribed extracting liquid is capable of using in place of the alcoholic extract of Impatience balsamina L.
A clinical recommendation method, a clinical recommendation apparatus, and a computer-readable recording medium are provided. In the method, Each medical parameter is determined as an independent event. Each medical parameter has an actual diagnosis. The independent event is defined that a medical parameter is independent of the actual diagnosis thereof. Multiple reference probabilities of each medical parameter are determined based on a probabilistic model. Each reference probability is a probability of one medical parameter in a condition where one reference diagnosis occurs. Multiple final probabilities of reference diagnoses are determined according to the reference probabilities of the medical parameters. A recommendation is determined according to the final probabilities of the reference diagnoses. Accordingly, a proper recommendation may be provided.
Metabolic control of diabetes, measured by hemoglobin A1c (HbA1c), reduces the risk of microvascular complications. Health care providers frequently do not meet standards for managing HbA1c and individuals with diabetes are often not aware of their HbA1c values. To address these issues and reduce population-attributable risk due to elevated HbA1c, the New York City Department of Health and Mental Hygiene (DOHMH) developed an innovative HbA1c registry, which requires all major laboratories to report HbA1c results electronically. We propose to utilize this registry to conduct a randomized controlled trial addressing the following specific aims: 1) to evaluate the incremental effect of a tiered and tailored, patient-centered telephone intervention, in English and Spanish, on the mean HbA1c levels beyond that achieved with print materials mailed to patients and providers by the DOHMH registry intervention; 2) determine what patient demographic and psychosocial factors mediate the effect of the interventions; and 3) provide estimates of implementation costs of the tiered, tailored telephone intervention for comparison with the print intervention. The individual is the unit of sampling, assignment and analysis. After eligibility is assessed and informed consent is obtained by telephone, the individual will be randomly assigned to one of the two groups. The patient telephone intervention will focus on collaborative problem solving for resolving barriers to medication adherence, improving lifestyle behaviors, and communicatiing effectively with their providers. The print materials from the DOHMH will communicate HbA1c results to patients and their providers, with strategies to improve them. The study outcome will be change in HbA1c values from the registry records from baseline to one-year post-randomization. A total of 941 individuals with diabetes will be needed to provide 83% power to detect a statistically significant difference (p\<0.05) between groups of at least 0.3% in absolute HbA1c. Psychosocial data on depression, health behaviors, and risk perceptions will be collected by telephone. Intervention cost data will be evaluated for translation of findings and scalability. At study end, we will know the extent to which this intervention will improve metabolic control in a low-income, multi-ethnic sample who are part of the DOHMH HbA1c registry in the South Bronx, New York. These findings will inform public health policies and practices in New York City, as well as other urban areas throughout the nation.
A NaOCl-based gel will initially be applied in the peri-implant sulcus for 30 seconds, without the need for flushing. Furthermore, mechanical therapy (NSMD) will be performed by means of an ultrasonic scaler with a plastic tip. Finally, the HA-based gel will be applied in the peri-implant sulcus by means of a blunt-tipped needle.
The invention relates to an anti-depression composition and a preparation method thereof and especially relates to an anti-depression traditional Chinese medicine composition and a preparation method thereof. The anti-depression traditional Chinese medicine composition solves the problem that the existing anti-depression medicine has large side effects, cannot simultaneously treat principal and subordinate symptoms, has a high cost and is not suitable for large-scale production. The anti-depression traditional Chinese medicine composition comprises 1500-15000 parts of licorice root and 500-10000 parts of coptis root. The preparation method comprises extracting licorice root extract and coptis root extract, mixing 30-450 parts of the licorice root extract and 5-150 parts of the coptis root extract, and adding an accessory material into the mixture. The medicinal components of the anti-depression traditional Chinese medicine composition produce synergism, and compared with single licorice root or licorice root extract, and single coptis root or coptis root extract, the anti-depression traditional Chinese medicine composition has greatly improved effects, low toxicity, high safety and good stability. The anti-depression traditional Chinese medicine composition is used for the field of anti-depression medicines.
BACKGROUND AND OBJECTIVES: Haemostasis-related complications associated with Medtronic Tri-stapleTM with preloaded buttress material and the novel, naked AEONTM gastrointestinal staplers have not been extensively studied in bariatric surgery. The study aimed to assess and compare the 30-day haemostasis-related complications between Medtronic Tri-stapleTM and AEONTM GIA staplers.
METHODS: A retrospective analysis was performed on data from patients who underwent primary or revision sleeve gastrectomy (SG) or the sleeve component of single anastomosis duodeno-ileal bypass with SG (SADI-S) in a private hospital in Australia between November 2021 and December 2022. The surgeries were performed by a single surgeon, using either Medtronic Tri-stapleTM or AEONTM staplers.
RESULTS: The analysis included 250 patients, with the first 125 consecutive patients receiving staple line using the Medtronic Tri-stapleTM GIA stapler and the subsequent 125 patients receiving staple line using the AEONTM GIA stapler. Statistical analysis revealed no significant differences in the distribution of surgical procedures between the Medtronic and AEON groups. In the AEON group, there were statistically higher numbers of diabetics and former tobacco users, while other preoperative characteristics did not significantly differ between the two groups. The AEON group had a significantly longer mean operative time, while the length of hospital stay was significantly shorter. No intraoperative or 30-day complications, deaths, emergency room visits, readmissions, or reoperations were observed in either group.
CONCLUSION: The novel, naked AEONTM stapler demonstrated non-inferiority to the established Medtronic Tri-StapleTM with preloaded buttress material in achieving hemostasis and maintaining staple-line integrity in bariatric surgery.
Patients with localized recurrent PFEPN will be treated with IT trastuzumab following 5-day course of subQ GM-CSF. Surgical resection should be planned (based on institutional surgical scheduling standards) for ideally 2-7 days after IT trastuzumab dosage.
INTRODUCTION: Socio-psychological factors such as fear of recurrence and presence of social support may affect quality of life (QOL) of cancer patients. Identifying mediating factors that impact QOL are crucial for targeting vulnerability in patients undergoing cancer treatments. The study purpose was therefore to determine relationships between presence of fear of cancer recurrence and QOL of patients, with the mediating role of social support.
METHODS: A predictive correlational design was used to conduct the study with 300 patients with cancer who were undergoing chemotherapy, radiotherapy, or surgery at two medical centers in Tehran. Measures included a demographic information form, the Fear of Cancer Recurrence Inventory (FCRI), the European Organization for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30), and the Multidimensional Scale of Perceived Social Support (MSPSS). Data analyses included descriptives, and path analysis analyses.
RESULTS: Higher fear of cancer recurrence predicted lower QOL (β = -0.60, p < 0.001). Moreover, individuals with lower fear of cancer recurrence also perceived higher social support (β = 0.32, p < 0.001). Additionally, individuals with higher perceived social support also reported better QOL (β = 0.30, p < 0.001).
CONCLUSION: Perceived social support plays a significant mediating role in the relationship between the fear of cancer recurrence and QOL in patients undergoing active cancer treatment. Enhancing social support among cancer patients may contribute to enhanced QOL, and as does reducing fears associated with disease recurrence.
Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via "weighing the evidence"; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs.
To investigate the feasibility of absorbable screws as a new fixation material for the treatment of ASIS avulsion fractures in children and adolescents.The investigator plan to retrospectively analyzed 59 patients diagnosed with ASIS avulsion fractures in our hospital between Jan 2009 and Dec 2016. These patients were divided into two groups: group A (conservative group) and group B (absorbable screws). Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws. Six weeks and three months after treatment, all patients were assessed for range of motion (ROM) and by X-ray as they returned to activity. One week after treatment, the American Academy of Orthopaedic Surgeons (AAOS) lower limb and hip score was used to evaluate hip function; the same scores were also determined during follow-up at 1, 3, 6 and 12 months postoperatively.
A method of making medicinal capsules comprising medicines in predetermined doses dispersed in a carrier comprises preparing a solution or dispersion of the medicine in an aqueous solution of a swellable colloid, e.g., gelatin, agar-agar, gum acacia, pectin, starch, tragacanth or casein, warming the solution, e.g., to 50 DEG C. and adding dropwise to a water immiscible liquid of lower density than the solution or dispersion and which is contained in a tall cylinder, the top part of which is maintained at a temperature akin to the solution and the bottom of which is maintained at a temperature at which the colloidal carrier is solid.  The droplets, as they descend the cylinder congeal to form solid "pearls" containing an amount of medicine determined by the size of each droplet.  Specification 708,160 [Group VI] is referred to.ALSO:A method of preparing medicines in doses dispersed in a carrier, comprises preparing a solution or dispersion of the medicine in an aqueous solution of a swellable colloid, e.g. gelatin, agar-agar, gum acacia, pectin, starch, tragacanth or casein.  This solution or dispersion is then added dropwise, after warming, e.g. to 50 DEG  C., to a water-immiscible liquid of lower density than the solution or dispersion and which is also a non-solvent for the medicine, e.g. paraffin oil, or an animal or vegetable oil.  This liquid is contained in a tall vertical vessel, the top part of which is maintained at a temperature similar to the colloidal dispersion or solution, e.g. 50 DEG  C., and the bottom of which is at a lower temperature, e.g. 20 DEG  C.  On descending the vessel the drops congeal forming "pearls," containing the medicine dispersed in the carrier.  The "pearls" are incompletely washed with benzene to remove part of the adhering oil, dried and washed free of all oil.  Water may be removed with a water-miscible solvent, e.g. acetone, methanol, ethanol, propanol or dioxan.  The colloidal solution may also contain a plasticizing agent, e.g. glucose, sorbitol, glycol or hevey.  If the medicine has been incorporated in an oil form and clear "pearls" are required, resin may be added to the oil phase of the dispersion to equalize the refractive indices of the two phases.  The pH of the colloidal solution or dispersion is adjusted closely to the isoelectric point of the swellable colloid used, before pouring dropwise into the congealing medium.  If a cellulose derivative, e.g. carboxymethyl cellulose, is used as the carrier, the coagulating vessel may contain an aqueous solution of an acid, or an organic solvent.  The example given is for a multivitamin preparation. Specification 708,160 is referred to.
PURPOSE:To provide a chemical embolization treatment agent composed of a coarse crystal of a hardly soluble carcinostatic agent having an average particle diameter falling within a specific range and exhibiting activated physical and chemical properties of the single carcinostatic agent without using a raw material for drug preparation. CONSTITUTION:The objective agent for chemical embolization treatment is composed of coarse crystals of a hardly soluble carcinostatic agent (e.g. platinum complex compound, epoxide or adriamycin) having an average particle diameter of 10-1,500mum, especially 50-800mum and a water-solubility of <=5wt.%, especially <=1wt.% at 37 deg.C. Said coarse crystalc an be prepared by growing a crystal spending a long period by spontaneous cooling or keeping at or above the room temperature (20 deg.C or above) in recrystallization. The fraction of the crystalline state of the coarse crystal exhibits the embolization effect in a living tissue and the dissolved fraction exhibits the carcinostatic action. The agent acts as a chemical embolizaiton treatment agent by the competitive action of both fractions.
Patients and caregivers randomized to this arm will receive a packet of educational materials in English or Spanish. These materials are written at 5-6th grade reading level. The materials focus on advance care planning, pain and symptom management, and hospice care.
Observation of lung changes over time by hyperpolarized xenon MRI on CF patients homozygous for F508del CFTR mutation as they age into the FDA approved treatment window for the CFTR modulator orkambi. Subjects will be observed at 2 time points before starting clinically prescribed treatment (orkambi) and 2 time points while on orkambi.
The present invention provides a preservative free ophthalmic formulation. In particular, the ophthalmic formulations of the invention are aqueous formulations comprising nanoemulsion of oil. The present invention also provides a method for treating an eye disorder. In one particular embodiment, the invention provides methods for treating dry eye syndrome using an preservative free formulation comprising a nanoemulsion of oil and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof. In particular, the alpha 2 adrenergic agonist of the invention has a higher alpha 2A agonist activity compared to alpha 2B agonist activity. This invention also provides a preservative free ophthalmic composition comprising a nanoemulsion of oil, a therapeutically effective amount of an alpha 2 adrenergic agonist, a pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient for treating a dry eye syndrome.
The most popular treatment for end-stage renal illness is hemodialysis (HD). The study aimed to assess serum ferritin levels and their connection to Epoetin alfa resistance, along with exploring the link between hepatitis C virus, iron overload, and the prevalence of hepatitis C and B infections in chronic HD patients. This was a descriptive-analytical study conducted on 50 Patients with chronic kidney disease (CKD) who were on regular HD in the dialysis unit of Ibin Sina Teaching Hospital in Mosul City, Iraq. Out of 50 patients, 26 (52%) tested positive for Hepatitis C Virus (HCV) Antibody, 10 (20%) for Hepatitis B surface Antigen (HBsAg), and 14 (28%) tested negative for both. Higher serum iron and ferritin levels were found in HCV antibody-positive patients (p < 0.05). Despite Epoetin alfa treatment, patients with elevated ferritin levels exhibited lower Hemoglobin (HB) and Packed Cell Volume (p < 0.05). Non-diabetics exhibited significantly higher serum ferritin, Hemoglobin, Blood urea, and serum creatinine than diabetics (p < 0.05). A noteworthy association was seen between the quantity of blood transfusions and elevated levels of serum ferritin and total serum iron (p < 0.05). Most HD patients were anemic, with Hepatitis B and C prevalent. The main CKD causes were diabetes and hypertension. HCV-positive patients often showed mild to moderate iron overload, and high serum ferritin was linked to poor Epoetin alfa response. Dialysis can elevate blood urea, ferritin, and creatinine, worsening anemia. High ferritin levels may hinder response to Epoetin alfa and iron replacement. Excessive blood transfusions can lead to iron overload and inhibit erythropoiesis. Maintaining HB at 110-120 g/l improves quality of life and reduces anemia-related risks.
INTRODUCTION: Avascular necrosis (AVN) is a rare progressive degenerative disease leading to bone and joint destruction. Patients often require surgical intervention. Femoral AVN is the most common anatomical location. Hyperbaric oxygen treatment (HBOT) has been shown to be effective in AVN. We present data collected from one centre over a 30-year period and compare the results with other published data.
METHODS: A retrospective chart review of all patients receiving HBOT for AVN at Fremantle and Fiona Stanley Hospitals since 1989 was performed. The primary outcome was radiological appearance using the Steinberg score, with secondary outcomes being subjective improvement, the need for joint replacement surgery and rates of complications.
RESULTS: Twenty-one joints in 14 patients (14 femoral heads and seven femoral condyles) were treated with HBOT since 1989. Two patients were excluded. Within the femoral head group, nine of the 14 joints (64%) had stable or improved magnetic resonance imaging (MRI) scans post treatment and at six months (minimum); 10 joints (71%) had good outcomes subjectively, three joints required surgical intervention, and three patients developed mild aural barotrauma. Within the femoral condyle group, all five joints had stable or improved post-treatment MRI scans (four had visible improvement in oedema and/or chondral stability), four joints reported good outcomes subjectively, none of the patients required surgical intervention (follow-up > six months).
CONCLUSIONS: This single centre retrospective study observed prevention of disease progression in femoral AVN with the use of HBOT, comparable to other published studies. This adds to the body of evidence that HBOT may have a significant role in the treatment of femoral AVN.
A surgical robotic system may comprise a manipulator assembly including a manipulator arm having a distal portion. The surgical robotic system may also comprise a registration device mounted to a surgical table. The table mounted registration device includes a registration element shaped to contact with the distal portion of the manipulator arm by receiving the distal portion of the manipulator arm to define a spatial relationship between the manipulator assembly and the table mounted registration device. The distal portion of the manipulator arm moves in a plurality of degrees of freedom. The plurality of degrees of freedom is reduced by the table mounted registration device when the table mounted registration device is in contact with the distal portion of the manipulator arm. The surgical robotic system may also comprise a control system that determines the spatial relationship between the manipulator assembly and the table mounted registration device.
From 18 to 35 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.